相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C. E. Geyer et al.
ANNALS OF ONCOLOGY (2022)
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study*
L. Gianni et al.
ANNALS OF ONCOLOGY (2022)
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
Thomas Bachelot et al.
NATURE MEDICINE (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Paradigms on Immunotherapy Combinations with Chemotherapy
Diego Salas-Benito et al.
CANCER DISCOVERY (2021)
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai S. Alva et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab plus pertuzumab plus trastuzumab plus chemotherapy (neoadj A plus PH plus CT) in high-risk, HER2-positive early breast cancer (EBC)
J. Huober et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
P. Schmid et al.
ANNALS OF ONCOLOGY (2021)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
Daisuke Okajima et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial
Sara M. Tolaney et al.
JAMA ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F. Poggio et al.
ANNALS OF ONCOLOGY (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A. Schaer et al.
CELL REPORTS (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Classical pathology and mutational load of breast cancer - integration of two worlds
Jan Budczies et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2015)
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
Ezzeldin M. Ibrahim et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)